Midstage trial proceeds for sickle cell disease drug

01/22/2013 | Pharmaceutical Business Review Online

Enrollment has been wrapped up for a midstage study evaluating the safety, efficacy and pharmacokinetics of GlycoMimetics' experimental drug GMI-1070 among sickle cell disease patients in vaso-occlusive crisis. Preliminary findings from the 76-patient trial could be released next quarter.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL